CVMP fandt derfor, at ovennævnte rapporter giver gunstigt vidnesbyrd om sikkerheden og virkningen for doxycyclin generelt, men også for færdigproduktet i den i Spanien markedsførte formulering.
Therefore, the CVMP considered that the reports mentioned above give favourable evidence for the safety and efficacy of doxycycline in general, but also for the specific final formulation as marketed in Spain.